[go: up one dir, main page]

PE20120016A1 - Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion - Google Patents

Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion

Info

Publication number
PE20120016A1
PE20120016A1 PE2011001264A PE2011001264A PE20120016A1 PE 20120016 A1 PE20120016 A1 PE 20120016A1 PE 2011001264 A PE2011001264 A PE 2011001264A PE 2011001264 A PE2011001264 A PE 2011001264A PE 20120016 A1 PE20120016 A1 PE 20120016A1
Authority
PE
Peru
Prior art keywords
ona
pyridazin
pyrimidin
phosphate
methyl
Prior art date
Application number
PE2011001264A
Other languages
English (en)
Inventor
Axel Becker
Clemes Kuehn
Christoph Saal
Oliver Schadt
Dieter Dorsch
Frank Stieber
Eva Kriegsbaum
Cristina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20120016A1 publication Critical patent/PE20120016A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA AL DIHIDROGENO-FOSFATO DE 6-(1-METIL-1H-PIRAZOL-4-IL)-2-{3-[5-(2-MORFOLIN-4-IL-EXTOXI)-PIRIMIDIN-2-IL]-BENCIL}-2H-PIRIDAZIN-3-ONA, SUS SOLVATOS Y FORMAS CRISTALINAS TAL COMO LA FORMA CRISTALINA A1 CARACTERIZADA POR SUS PICOS DE XRD 18,4º, 18,8º, 23,7º, 24,2º, 26,4º Y 28,2º 2 THETA (±0,1º 2THETA) EMEPLEANDO UNA RADIACION Cu-KALFA1 O LA FORMA CRISTALINA H1 CON PICOS DE XRD DE 3,1º, 9,4º Y 18,8º 2 THETA (±0,1º 2THETA). TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTCA Y A UN PROCESO DE PREPARACION. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR QUINASAS
PE2011001264A 2008-12-22 2009-11-24 Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion PE20120016A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08022253 2008-12-22

Publications (1)

Publication Number Publication Date
PE20120016A1 true PE20120016A1 (es) 2012-01-24

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001264A PE20120016A1 (es) 2008-12-22 2009-11-24 Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion

Country Status (31)

Country Link
US (1) US8586599B2 (es)
EP (1) EP2361250B1 (es)
JP (2) JP5690741B2 (es)
KR (1) KR101663335B1 (es)
CN (1) CN102264729B (es)
AR (1) AR074686A1 (es)
AU (1) AU2009331990B2 (es)
BR (1) BRPI0923480B8 (es)
CA (1) CA2748218C (es)
CL (1) CL2011001278A1 (es)
CO (1) CO6331435A2 (es)
CY (1) CY1114659T1 (es)
DK (1) DK2361250T3 (es)
EA (1) EA019320B1 (es)
EC (1) ECSP11011219A (es)
ES (1) ES2434247T3 (es)
HR (1) HRP20130993T1 (es)
IL (1) IL213647A (es)
MX (1) MX2011006682A (es)
MY (1) MY160526A (es)
NZ (1) NZ594172A (es)
PE (1) PE20120016A1 (es)
PL (1) PL2361250T3 (es)
PT (1) PT2361250E (es)
SG (1) SG172128A1 (es)
SI (1) SI2361250T1 (es)
SM (1) SMT201300133B (es)
TW (1) TWI448463B (es)
UA (1) UA103646C2 (es)
WO (1) WO2010072295A1 (es)
ZA (1) ZA201105394B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
HUP0401984A3 (en) 2001-10-31 2005-06-28 Merck Patent Gmbh Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
MXPA06000091A (es) 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2006015263A2 (en) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
MY159523A (en) 2005-12-21 2017-01-13 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PE20091079A1 (es) 2007-10-16 2009-08-24 Novartis Ag Compuestos heterociclicos como moduladores npy y2
WO2009053737A2 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
KR20100084516A (ko) 2007-10-31 2010-07-26 닛산 가가쿠 고교 가부시키 가이샤 피리다지논 유도체 및 이의 ｐ2ｘ7 수용체 억제제로서의 용도
AR069545A1 (es) 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
PE20091669A1 (es) 2007-12-21 2009-12-06 Exelixis Inc Benzofuropirimidinonas
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
JP2011507824A (ja) 2007-12-21 2011-03-10 アストラゼネカ アクチボラグ アンドロゲン受容体関連状態の治療に使用の二環系誘導体
RU2489430C2 (ru) 2007-12-21 2013-08-10 Палау Фарма, С.А. Производные 4-аминопиримидина
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
WO2009080364A1 (en) 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
EP2234999A1 (en) 2007-12-21 2010-10-06 F. Hoffmann-La Roche AG Heteroaryl derivatives as orexin receptor antagonists
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
WO2010010150A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
WO2010113986A1 (ja) 2009-03-30 2010-10-07 住友化学株式会社 ピリダジノン化合物の有害節足動物防除用途
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
ES2434247T3 (es) 2013-12-16
EA201100973A1 (ru) 2012-01-30
BRPI0923480A2 (pt) 2016-08-09
JP5860125B2 (ja) 2016-02-16
BRPI0923480B1 (pt) 2020-10-13
US20110257180A1 (en) 2011-10-20
BRPI0923480B8 (pt) 2021-05-25
SMT201300133B (it) 2014-03-07
MY160526A (en) 2017-03-15
TWI448463B (zh) 2014-08-11
SI2361250T1 (sl) 2013-12-31
MX2011006682A (es) 2011-07-13
ECSP11011219A (es) 2011-12-30
HRP20130993T1 (hr) 2013-11-22
PL2361250T3 (pl) 2014-01-31
CA2748218C (en) 2017-08-29
CN102264729A (zh) 2011-11-30
CO6331435A2 (es) 2011-10-20
IL213647A0 (en) 2011-07-31
WO2010072295A1 (en) 2010-07-01
JP2012513417A (ja) 2012-06-14
US8586599B2 (en) 2013-11-19
AU2009331990A1 (en) 2011-08-11
CL2011001278A1 (es) 2011-09-30
AR074686A1 (es) 2011-02-02
AU2009331990B2 (en) 2016-04-14
UA103646C2 (ru) 2013-11-11
DK2361250T3 (da) 2013-11-04
SG172128A1 (en) 2011-07-28
KR20110089462A (ko) 2011-08-08
PT2361250E (pt) 2013-11-11
HK1164837A1 (en) 2012-09-28
EP2361250A1 (en) 2011-08-31
CN102264729B (zh) 2014-03-05
IL213647A (en) 2013-11-28
JP5690741B2 (ja) 2015-03-25
JP2015028093A (ja) 2015-02-12
KR101663335B1 (ko) 2016-10-06
TW201028409A (en) 2010-08-01
CY1114659T1 (el) 2016-10-05
ZA201105394B (en) 2012-03-28
CA2748218A1 (en) 2010-07-01
EA019320B1 (ru) 2014-02-28
NZ594172A (en) 2013-04-26
EP2361250B1 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
PE20141317A1 (es) Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
PT2134702T (pt) Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-(piridin-2-il)etenil]indazol adequadas para o tratamento de crescimento celular anormal em mamíferos
BR112012002628A2 (pt) "composição para tratamento de infecções por hbv"
CL2007003627A1 (es) Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias
CL2007002669A1 (es) Compuestos derivados de benzoxazol-2,7-disustituido y oxazol[5,4-c]-piridina; proceso de fabricacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por las cinasas jack2 y/o jack3 tal como cancer.
CL2007003487A1 (es) Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno, inhibidor del transportador de glucosa sodio-dependiente; proceso de preparacion; composicion farmaceutica, util para el tratamiento de dia
BRPI0810411A2 (pt) Derivados de sulfonil amida para o tratamento de crescimento celular anormal
MX2010012298A (es) Activadores de glucocinasa.
CL2013000850A1 (es) Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
ZA201000491B (en) New antimicrobial compounds, their synthesis and their use for treatment of mammalian infections
PL2349962T3 (pl) Sposób wytwarzania chlorofluorowodoroolefin
EP2179966A4 (en) PROCESS FOR PRODUCING CERAMIC NANOPARTICLES
DK2114386T3 (da) Farmaceutisk sammensætning til behandling af diabeteskomplikationer
PA8666701A1 (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
CR20110625A (es) Compuestos biciclicos y triciclicos como inhibidores de kat ii
CL2008003067A1 (es) Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios.
EP2210873A4 (en) PROCESS FOR PREPARING POLYISOCYANATE
DOP2010000373A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
EP2402040A4 (en) BONE CEMENT COMPOSITION, MANUFACTURING METHOD AND KIT FOR ITS MANUFACTURE
BRPI0912388A2 (pt) composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças
EP2138505A4 (en) METHOD FOR PRODUCING HIGH-PURITY SOLUBLE THROMBOMODULINE
UY33628A (es) Nuevo monohidrato de derivados de aza-adamantano
IL208951A0 (en) Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1h-pyrrole-3-carboxamides

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed